As Medicare’s Maximum Fair Prices (MFPs) for the first ten selected drugs have finally been released, IRA is again at the forefront of forecasting, market access, patient services, and BD/portfolio strategy teams' minds as they grapple with the future prospects of their lead development programs. Strategically setting price and cost of access as assets approach launch is no longer enough to realize the full value of a program – teams must now consider how to maximize value even as they select candidates for clinical development. Join Triangle Insights Group for an interactive presentation where our Pricing and Market Access and New Product Planning leadership outlines potential approaches to maximize near-term ROI and long-term revenue potential in the age of IRA drug pricing provisions, including:
- A general overview of key updates to IRA drug pricing provisions from the most recent guidance
- The evolution of strategies for candidate selection and development in the context of the IRA drug pricing provisions
- An interactive product profile selection and design process based on characteristics favorable to the IRA landscape
